Riskpilot← Back to searchSign inGet full accessVicore Pharma AB
ABActiveOrg 5566070743Kornhamnstorg 53Research and experimental development on natural sciences and engineering · NACE 7210Est. 20015-9 employees
Revenue 2024
SEK 109,3M
+20807% vs 2023
EBITDA margin
-205.5%
+17% vs 2023
Equity ratio
19.4%
Financial strength
Net profit 2024
SEK -216,5M
+23% vs 2023
| Revenue | SEK 109,3M | +20807% |
| EBITDA | SEK -224,7M | +17% |
| Net profit | SEK -216,5M | +23% |
| Total assets | SEK 154,1M | +35% |
| Equity | SEK 29,9M | -32% |
| Employees | — | — |
Legal name
Vicore Pharma AB
Org number
5566070743
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 februari 2001
Share capital
SEK 100 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska på kommersiella grunder bedriva forskning och utveckling av nya läkemedel inom sjukdomsområden, indikationsområden vars effekter medieras av AT2 receptorer samt idka därmed förenlig verksamhet.
Address
Kornhamnstorg 53
Phone
+46317880560
Email
info@vicorepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 216 | 3 996 | 2 973 | 2 936 | 2 841 | 523 | 109 346 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −2 365 | −3 675 | −7 943 | −28 951 | −60 563 | −98 167 | −289 873 | −276 303 | −269 735 | −224 658 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −515 | −1 558 | −1 558 | −1 558 | −13 558 | −1 044 |
| EBIT | −2 365 | −3 675 | −7 943 | −28 951 | −61 078 | −99 725 | −291 431 | −277 861 | −283 293 | −225 702 |
| Net financials | −237 | −745 | −620 | −1 431 | −1 | −1 | −433 | 1 716 | 1 451 | 9 199 |
| Profit before tax | −2 602 | −4 420 | −8 563 | −30 382 | −61 079 | −99 726 | −291 864 | −276 145 | −281 842 | −216 503 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 602 | −4 420 | −8 563 | −30 382 | −61 079 | −99 726 | −291 864 | −276 145 | −281 842 | −216 503 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 34 324 | 48 539 | 64 504 | 92 916 | 35 706 | 42 377 | 186 987 | 122 401 | 114 353 | 154 144 |
| Equity | 22 950 | 18 530 | 41 367 | 87 042 | 26 339 | 17 140 | 95 362 | 72 261 | 43 752 | 29 866 |
| Long-term debt | 10 155 | 26 936 | 19 930 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 219 | 3 073 | 3 207 | 5 874 | 9 293 | 24 371 | 91 380 | 49 157 | 69 791 | 123 998 |
| Total debt | 11 374 | 30 009 | 23 137 | 5 874 | 9 293 | 24 371 | 91 380 | 49 157 | 69 791 | 123 998 |
EBITDA margin
-205.5%
This company
15.8%
Market median
-1401% vs market
20152024
Equity ratio
19.4%
This company
38.2%
Market median
-49% vs market
20152024
Return on equity
-724.9%
This company
18.4%
Market median
-4040% vs market
20152024
Net profit margin
-198.0%
This company
8.1%
Market median
-2544% vs market
20152024
Asset turnover
0.71×
This company
1.12×
Market median
-37% vs market
20152024
Debt / equity
4.16×
This company
0.62×
Market median
-571% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
LE Chief Auditor | Chief Auditor | 2022 | — | — |
AG Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Vicore Pharma Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vicore Pharma Holding AB
Vicore Pharma AB Board members of Vicore Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Johan Dalsgaard | Chief Executive Officer | 0 companies |
| Linda Elisabeth Sallander | Chief Auditor | 0 companies |
| Andreas Gunnar Mast | Chief Auditor | 0 companies |
| Hans Lennart Jeppsson | Deputy Board Member | 0 companies |
| Ahmed Shaker Mousa | Board of Directors | 0 companies |